Targeting pro‐survival members of the BCL‐2 family is an attractive therapeutic option in MM but reliance on BCL‐2, MCL‐1 and BCL‐XL for survival has been shown to be variable (Touzeau et al 2014). The gene discussed is MCL1; the disease is Miyoshi myopathy.